Viking TherapeuticsRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Q3 2016-Q2 2026
Q3 2016-Q2 2026
Viking TherapeuticsClinical-stage biotech. VK2735: dual GLP-1/GIP in oral and injectable formulations; VENTURE-Oral Phase 2 hit 10.9% placebo-adjusted weight loss at 13 weeks. Most-discussed mid-cap obesity pure-play.
Viking Therapeutics (VKTX) is a Biotechnology company. Clinical-stage biotech. VK2735: dual GLP-1/GIP in oral and injectable formulations; VENTURE-Oral Phase 2 hit 10.9% placebo-adjusted weight loss at 13 weeks. Most-discussed mid-cap obesity pure-play. It was founded in 2012, is headquartered in San Diego, CA and employs about 35 people.
Track Viking Therapeutics's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 23, 2026.
Sterling groups Viking Therapeutics in the GLP-1 sector, alongside Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE), Amgen (AMGN), Roche (RHHBY) and AstraZeneca (AZN).
If you are researching Viking Therapeutics, also look at Eli Lilly (LLY), Novo Nordisk (NVO) and Pfizer (PFE). You can compare all of them side by side or browse the full GLP-1 sector on Sterling.